Catalyst Pharmaceuticals recently announced a postponement of its critical bench trial concerning FIRDAPSE® patent validity, extending exclusive rights protection risks into mid-2026. This delay underscores the ongoing litigation dynamics impacting its flagship orphan drug’s competitive landscape. Catalyst’s core business model capitalizes on niche orphan and rare disease markets with proprietary products benefiting from regulatory exclusivities, backed by strong liquidity and experienced leadership. Future growth will hinge on pipeline progression, commercial expansion, and navigating pricing and tariff-related headwinds.